Does the Naked Emperor Parable Apply to Current Perceptions of the Contribution of Renin Angiotensin System Inhibition in Hypertension?

• Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591–603. https://doi.org/10.1161/HYPERTENSIONAHA.120.16667.

Ferrari R, Rosano GM. Not just numbers, but years of science: putting the ACE inhibitor-ARB meta-analyses into context. Int J Cardiol. 2013;166(2):286–8. https://doi.org/10.1016/j.ijcard.2013.01.027.

Article  CAS  PubMed  Google Scholar 

Ranganathan P, Pramesh CS, Aggarwal R. Common pitfalls in statistical analysis: absolute risk reduction, relative risk reduction, and number needed to treat. Perspect Clin Res. 2016;7(1):51–3. https://doi.org/10.4103/2229-3485.173773.

Article  PubMed  PubMed Central  Google Scholar 

•• Turnbull F, Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35. https://doi.org/10.1016/s0140-6736(03)14739-3.

Akobeng AK. Understanding measures of treatment effect in clinical trials. Arch Dis Child. 2005;90(1):54–6. https://doi.org/10.1136/adc.2004.052233.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blood Pressure Lowering Treatment Trialists C, Turnbull F, Neal B, Ninomiya T, Algert C, Arima H et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336(7653):1121–3. https://doi.org/10.1136/bmj.39548.738368.BE.

• Blood Pressure Lowering Treatment Trialists C, Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25(5):951–8. https://doi.org/10.1097/HJH.0b013e3280bad9b4.

Effects of ACE inhibitors. calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. The Lancet. 2000;356(9246):1955–64. https://doi.org/10.1016/S0140-6736(00)03307-9.

Article  Google Scholar 

• Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. The Lancet. 2014;384(9943):591–8. https://doi.org/10.1016/S0140-6736(14)61212-5.

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625–36. https://doi.org/10.1016/s0140-6736(21)00590-0.

Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Curr Pharm Des. 2007;13(13):1335–45. https://doi.org/10.2174/138161207780618768.

Article  CAS  PubMed  Google Scholar 

Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(10 Suppl):1 K-34 K. https://doi.org/10.1016/S0002-9149(08)01833-X.

•• Vanuzzo D. The epidemiological concept of residual risk. Intern Emerg Med. 2011;6 Suppl 1:45–51. https://doi.org/10.1007/s11739-011-0669-5.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13–115. https://doi.org/10.1161/HYP.0000000000000065.

Article  CAS  PubMed  Google Scholar 

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–57. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026.

Article  CAS  PubMed  Google Scholar 

Elijovich F, Kleyman TR, Laffer CL, Kirabo A. Immune mechanisms of dietary salt-induced hypertension and kidney disease: Harry Goldblatt Award for Early Career Investigators 2020. Hypertension. 2021;78(2):252–60. https://doi.org/10.1161/HYPERTENSIONAHA.121.16495.

Article  CAS  PubMed  Google Scholar 

Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957–63. https://doi.org/10.1056/NEJM199812313392701.

Article  CAS  PubMed  Google Scholar 

Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–32. https://doi.org/10.1038/s41591-019-0675-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev. 2007;65(12 Pt 2):S140–6. https://doi.org/10.1111/j.1753-4887.2007.tb00352.x.

Article  PubMed  Google Scholar 

Xiao L, Harrison DG. Inflammation in hypertension. Can J Cardiol. 2020;36(5):635–47. https://doi.org/10.1016/j.cjca.2020.01.013.

Article  PubMed  Google Scholar 

Madhur MS, Elijovich F, Alexander MR, Pitzer A, Ishimwe J, Van Beusecum JP, et al. Hypertension: do inflammation and immunity hold the key to solving this epidemic? Circ Res. 2021;128(7):908–33. https://doi.org/10.1161/CIRCRESAHA.121.318052.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fink GD. Exaggerated sympathetic neurovascular transduction as a mechanism of neurogenic hypertension: it is not all about activity. Hypertension. 2018;71(1):64–5. https://doi.org/10.1161/HYPERTENSIONAHA.117.10300.

Article  CAS  PubMed  Google Scholar 

Oparil S. The sympathetic nervous system in clinical and experimental hypertension. Kidney Int. 1986;30(3):437–52. https://doi.org/10.1038/ki.1986.204.

Article  CAS  PubMed  Google Scholar 

Basile J, Houston M, Ferrario CM. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction. J Cardiometab Syndr. 2006;1(5):358–61. https://doi.org/10.1111/j.1559-4564.2006.06035.x.

Article  PubMed  Google Scholar 

Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93. https://doi.org/10.1056/NEJMoa021778.

Article  PubMed  Google Scholar 

• Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015;116(6):1074–95. https://doi.org/10.1161/CIRCRESAHA.116.303603.

Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174(5):773–85. https://doi.org/10.1001/jamainternmed.2014.348.

Article  CAS  PubMed  Google Scholar 

Ferrario CM, Dell Italia LJ, Varagic J. Molecular signaling mechanisms of the renin-angiotensin system in heart failure. In: Felker GM, Mann DL, editors. HEART FAILURE. A Companion to Braunwald's Heart Disease. Fourth Edition ed. Philadelphia, PA: ELSEVIER; 2020. p. 76–90.

Ferrario CM, Mullick AE. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res. 2017;125(Pt A):57–71. https://doi.org/10.1016/j.phrs.2017.05.020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Reyes S, Varagic J, Ahmad S, VonCannon J, Kon ND, Wang H et al. Novel cardiac intracrine mechanisms based on Ang-(1–12)/chymase axis require a revision of therapeutic approaches in human heart disease. Curr Hypertens Rep. 2017;19(2):16. https://doi.org/10.1007/s11906-017-0708-3.

Trask AJ, Ferrario CM. The renin–angiotensin system and the heart. In: Singh AK, Williams GH, editors. Textbook of Nephro-Endocrinology. San Diego: Academic Press; 2009. p. 181–8.

Chapter  Google Scholar 

Trask AJ, Ferrario CM. The renin–angiotensin system and the heart. In: Singh AK, Williams GH, editors. Textbook of Nephro-Endocrinology. Academic Press; 2018. p. 43–55.

Chapter  Google Scholar 

Dusing R. Mega clinical trials which have shaped the RAS intervention clinical practice. Ther Adv Cardiovasc Dis. 2016;10(3):133–50. https://doi.org/10.1177/1753944716644131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Dusing R, Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin. 2009;25(9):2287–301. https://doi.org/10.1185/03007990903152045.

Guidance for Industry. Hypertension indication: drug labeling for cardiovascular outcome claims In: (CDER) USDoHaHSFaDACfDEaR, editor. Silver Spring, MD 20993–0002: Food and Drug Administration; 2011.

Lieb W, Graf J, Gotz A, Konig IR, Mayer B, Fischer M et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. J Mol Med (Berl). 2006;84(1):88–96. https://doi.org/10.1007/s00109-005-0718-5.

• Brugts JJ, van Vark L, Akkerhuis M, Bertrand M, Fox K, Mourad JJ et al. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: a number-needed-to-treat analysis. Int J Cardiol. 2015;181:425–9. https://doi.org/10.1016/j.ijcard.2014.11.179.

van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–97. https://doi.org/10.1093/eurheartj/ehs075.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cushman WC, Goff DC Jr. More HOPE for prevention with statins. N Engl J Med. 2016;374(21):2085–7. https://doi.org/10.1056/NEJMe1603504.

Article  PubMed  Google Scholar 

Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021–31. https://doi.org/10.1056/NEJMoa1600176.

Article  CAS  PubMed  Google Scholar 

Fernandez-Atucha A, Izagirre A, Fraile-Bermudez AB, Kortajarena M, Larrinaga G, Martinez-Lage P, et al. Sex differences in the aging pattern of renin-angiotensin system serum peptidases. Biol Sex Differ. 2017;8:5. https://doi.org/10.1186/s13293-017-0128-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2012;32(9):856–68. https://doi.org/10.1002/j.1875-9114.2012.01108.x.

Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L. Body surface area in normal-weight, overweight, and obese adults. A comparison study Metabolism. 2006;55(4):515–24. https://doi.org/10.1016/j.metabol.2005.11.004.

Article  CAS  PubMed  Google Scholar 

• Ferrario CM, Ahmad S, Varagic J, Cheng CP, Groban L, Wang H et al. Intracrine angiotensin II functions originate from noncanonical pathways in the human heart. Am J Physiol Heart Circ Physiol. 2016;311(2):H404–14. https://doi.org/10.1152/ajpheart.00219.2016.

Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II–renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4(6):966–72.

Article  CAS  Google Scholar 

Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–10. https://doi.org/10.1161/CIRCULATIONAHA.104.510461.

Article  CAS  PubMed  Google Scholar 

Moniwa N, Varagic J, Ahmad S, VonCannon JL, Simington SW, Wang H, et al. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. Hypertension. 2013;61(2):417–24. https://doi.org/10.1161/HYPERTENSIONAHA.112.201889.

Article  CAS  PubMed  Google Scholar 

Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chroni

留言 (0)

沒有登入
gif